Baxter International (NYSE:BAX) has experienced a shortage of ifosfamide in Europe due to a technical issue at a third-party manufacturing facility. This disruption disrupted production planning, inventory systems, and product release cycles. The company is implementing a quota-based distribution system to manage existing inventory until supply normalizes. The shortage is not related to safety, efficacy or quality concerns, but is expected to vary by country. To mitigate the impact, Baxter is working with the European Medicines Agency and national regulators.